Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus-A Systematic Review and Meta-Analysis.
Arthritis Care Res (Hoboken)Apr 22, 2026 (epub)
Zahraa Qamhieh, Dalia Sriwi, Callie Saric et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of therapeutic drug level monitoring (TDM) of mycophenolate in patients with systemic lupus erythematosus (SLE), focusing on those with extrarenal manifestations. The study found that MPA levels at AUC 0-12 ≥30 to 35 mg hr/L or C trough ≥1.5 mg/L were associated with 12-fold higher odds of clinical response (95% CI 5.44-27.35; P < 0.0001).
Key findings
- Therapeutic MPA levels at AUC 0-12 ≥30 to 35 mg hr/L linked to 12-fold higher odds of overall clinical SLE response.
- Patients with extrarenal manifestations had 15-fold higher odds of response at the same MPA thresholds.
- Overall responders had MPA levels 32 units higher, while those with extrarenal manifestations had levels 39 units higher.
Why it matters
Monitoring mycophenolate levels can enhance treatment efficacy in SLE patients, particularly those with extrarenal manifestations, while also addressing safety concerns associated with higher drug levels.